Full Press Release Details
Flamel Technologies Announces New Feasibility Projects;
Technology Access Fee
LYON, France June 22, 2009 Flamel Technologies, SA (Nasdaq: FLML) today announced that it has
entered into agreements with a leading global healthcare provider to assess the applicability of
the Medusa platform for controlled release formulations of therapeutic proteins. The
Company will receive technology access fees totaling 2.5 million pursuant to these agreements,
plus full development costs for the program. A joint press release regarding the agreement is
anticipated for release in mid July.
Stephen H. Willard, Chief Executive Officer of Flamel Technologies, said: We are very pleased to
add a new partner for multiple molecules using our Medusa technology. We are gratified that our
technology has achieved the recognition which justifies upfront payments as well as the usual
license fees, development fees, milestones, and royalties. We look forward to announcing
additional details of our collaboration in the month to come.
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of
two unique polymer-based delivery technologies for medical applications. Micropump is a
controlled release and taste-masking technology for the oral administration of small molecule
drugs. Flamel s Medusa technology is designed to deliver controlled-release
formulations of therapeutic proteins and peptides, as well as small molecule drugs.
Charles Marlio, Director of Strategic Planning and Investor Relations
FRANCE: 33 (0) 4 7278-3434
Fax: 33 (0) 4 7278-3435
This document contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including certain plans, expectations, goals and projections
regarding financial results, product developments and technology platforms. All statements that
are not clearly historical in nature are forward-looking, and the words anticipate, assume,
believe, expect, estimate, plan, will, and similar expressions are generally intended to
identify forward-looking statements. All forward-looking statements involve risks, uncertainties
and contingencies, many of which are beyond our control, that could cause actual results to differ
materially from those contemplated in such forward-looking statements. These risks include risks
that products in the development stage may not achieve scientific objectives or milestones or meet
stringent regulatory requirements, uncertainties regarding market acceptance of products in
development, the impact of competitive products and pricing, and the risks associated with Flamel s
reliance on outside parties and key strategic alliances. These and other risks are described more
fully in Flamel s Annual Report on the Securities and Exchange Commission Form 20-F for the year
ended December 31, 2008. All forward-looking statements included in this release are based on
information available at the time of the release. We undertake no obligation to
update or alter our forward-looking statements as a result of new information, future events or